Other Clinical Trial - Mechanisms of Smell Improvement With Dupilumab.

Status Recruiting

Clinical Trial Summary

This study seeks to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with chronic sinusitis with nasal polyps (CRSwNP). The investigators expect this study to provide convincing evidence that dupilumab improves clinical olfaction via direct reduction in olfactory cleft inflammation.

Clinical Trial Description

Post-marketed administration of dupilumab (FDA approved medication for CRSwNP) in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) will result in significant improvement in objective measures of olfactory cleft inflammation and psychophysical olfaction. The investigators seek to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with CRSwNP. The investigators also want to determine whether change in olfactory cleft inflammation correlates with improvement in olfaction (one of the cardinal symptoms of CRSwNP) at 3 months. The investigators hypothesize that after 3 months of treatment with dupilumab, non-inflammatory factors will explain a significant degree of variation in residual clinical olfaction. Additionally, the investigators want to explore the determinants of ongoing olfactory loss after 3 months of treatment with attention to non-inflammatory factors. The investigators expect this study to provide convincing evidence that dupilumab improves clinical olfaction via direct reduction in olfactory cleft inflammation. Specifically, the investigators expect to show that reduction in olfactory cleft inflammation is the result of reduction in IL13 levels in olfactory cleft mucus. Finally, the investigators expect to show that most of the variation in post-treatment olfaction can be explained by non-inflammatory measures that are independent of CRSwNP. ;

Study Design

Related Conditions & MeSH terms

Chronic Rhinosinusitis With Nasal Polyps
Nasal Polyps

Clinical Trial Details

NCT number	NCT05964465
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Recruiting
Phase	Phase 4
Start date	August 10, 2023
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05895929` - The Role of IL5 in Epithelial Cell Integrity	Early Phase 1
Active, not recruiting	`NCT05891483` - Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps	Phase 2
Active, not recruiting	`NCT04998604` - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients	Phase 4
Recruiting	`NCT06069310` - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Recruiting	`NCT05009758` - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps	N/A
Active, not recruiting	`NCT05529784` - Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Recruiting	`NCT05902325` - Identifying Predictors Of Response To Mepolizumab In CRSwNP	Phase 4
Completed	`NCT05049122` - Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)	Phase 4
Not yet recruiting	`NCT05598411` - CST1-Guided Oral Glucocorticoids Management for CRSwNP	Phase 4
Active, not recruiting	`NCT05553951` - Adherence in Global Airways	N/A
Recruiting	`NCT05131464` - The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps	Phase 2
Recruiting	`NCT05598424` - CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps	Phase 4
Active, not recruiting	`NCT05649813` - A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
Recruiting	`NCT04628442` - Tissue Immune Interaction in Nasal Polyposis
Active, not recruiting	`NCT06118554` - 3D Printing to Improve Nasal Irrigation Outcome	N/A
Active, not recruiting	`NCT04596189` - Dupilumab for Prevention of Recurrence of CRSwNP After ESS	Phase 4
Recruiting	`NCT02668861` - Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels	Phase 3
Active, not recruiting	`NCT05878093` - Dupilumab in Chinese Adult Participants With CRSwNP	Phase 3
Completed	`NCT05931744` - The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis	Phase 2/Phase 3
Recruiting	`NCT05938972` - Real Life Study of Biologicals in Patients With Severe CRSwNP